Spinogenix’s SPG302 Oral Therapy Named Orphan Drug by FDA

Spinogenix’s SPG302 Oral Therapy Named Orphan Drug by FDA

296237

Spinogenix’s SPG302 Oral Therapy Named Orphan Drug by FDA

The U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to Spinogenix’s investigational oral molecule SPG302 for treating amyotrophic lateral sclerosis (ALS). Orphan drug status is granted by the FDA to encourage the development of therapies for conditions that affect fewer than 200,000 people in the U.S. It provides Spinogenix with certain benefits and incentives, such as assistance in clinical trial design, tax credits, and fee waivers, as well as seven years of…

You must be logged in to read/download the full post.